AR and prostate cancer: Aberrant SOX2 expression is noted, particularly in castration-resistant prostate cancer cells where ligand activation of AR promotes a decrease in SOX2 expression as a result of direct binding of the AR to the SOX2 cis-enhancer region [28,59].